BOL-148 substance abuse treatment method patent grant to Ceruvia Lifesciences
ChangeBridge: Patent Grants - Therapeutics (A61P)
Summary
The USPTO granted patent US12594272B2 to Ceruvia Lifesciences LLC covering a method of treating substance abuse using 2-bromo-lysergic acid diethylamide (BOL-148). The patent contains 6 claims and was filed on March 25, 2021, with Carey Turnbull listed as the inventor.
What changed
The USPTO issued patent grant US12594272B2 to Ceruvia Lifesciences LLC for a method of reducing substance use by administering BOL-148 (2-bromo-lysergic acid diethylamide) to an individual. This is a granted patent with enforceable exclusive rights in the US.
Pharmaceutical companies and drug manufacturers should note this patent position when developing psychedelic-based or LSD-derivative treatments for substance use disorders. Competitors may need to pursue licensing arrangements or design-around strategies to avoid infringement.
What to do next
- Monitor for updates
- Review freedom-to-operate for BOL-148 compounds
Source document (simplified)
2-bromo-lysergic acid diethylamide for substance abuse
Grant US12594272B2 Kind: B2 Apr 07, 2026
Assignee
Ceruvia Lifesciences LLC
Inventors
Carey Turnbull
Abstract
A method of treating substance abuses in an individual, by administering 2-bromo-lysergic acid diethylamide (BOL-148) to an individual and reducing use of the substance.
CPC Classifications
A61K 31/48 A61P 25/32
Filing Date
2021-03-25
Application No.
17913471
Claims
6
Related changes
Get daily alerts for ChangeBridge: Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Therapeutics (A61P) publishes new changes.